SK Biopharmaceuticals Co., Ltd.
326030 · KOSPI
Public Market Listing
Live quotes, historical charts, and market capitalization for SK Biopharmaceuticals Co., Ltd. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Cenobamate(Xcopri) | Approved | Sodium channels + GABA-A receptorsSmall molecule | Epilepsy Focal Onset Seizures |
Solriamfetol(Sunosi) | Approved | Dopamine/norepinephrine transporterSmall molecule | Major Depressive DisorderNarcolepsyAttention Deficit Hyperactivity Disorder |
| Phase 3 | Voltage-gated sodium channelSmall molecule | Epilepsy |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (5)
January 2027 (2)
February 2027 (1)
What to watch
2028 (4)
March 2028 (1)
What to watch
June 2028 (2)
December 2028 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
No financial reports recorded.